Akero Therapeutics, Inc.
AKRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,867,745 | $1,227,463 | $2,136,366 | $736,599 |
| - Cash | $340,238 | $234,207 | $249,773 | $150,483 |
| + Debt | $36,457 | $26,305 | $10,945 | $1,516 |
| Enterprise Value | $1,563,964 | $1,019,561 | $1,897,538 | $587,632 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$247,374 | -$148,631 | -$111,251 | -$100,736 |
| % Margin | – | – | – | – |
| Net Income | -$252,060 | -$151,759 | -$112,033 | -$100,777 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.75 | -2.89 | -2.87 | -2.89 |
| % Growth | -29.8% | -0.7% | 0.7% | – |
| Operating Cash Flow | -$230,107 | -$145,367 | -$92,517 | -$79,681 |
| Capital Expenditures | -$999 | $0 | $0 | $0 |
| Free Cash Flow | -$231,106 | -$145,367 | -$92,517 | -$79,681 |